PixarBio Corporation CEO Frank Reynolds to Receive The 2016 Irish America Magazine Healthcare & Life Sciences 50 Award at the Harvard Club on October 5, 2016 in New York City

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Today announced that Frank Reynolds Co-founder and CEO of PixarBio
Corporation, and inventors of NeuroRelease^TM, a novel
morphine replacement, non-opiate/opioid, non-addictive pain treatment,
will receive the 2016 Irish American Healthcare & Life Sciences 50 Award
at the Harvard Club in New York City on October 5, 2016. The annual
Irish America Healthcare & Life Sciences 50 Award recognizes the
excellence, performance, and extraordinary contributions of
Irish-American leaders in fields including medical care,
pharmaceuticals, biotechnology, medical devices, research and
development, and life sciences venture capital.

Frank Reynolds is the co-founder, CEO, CFO, CSO, and chairman of the
board of PixarBio Corporation, a Massachusetts-based specialty
pharma/biotechnology company. His father Frank Reynolds is from Cloone
County Leitrim, Ireland and was a successful entrepreneur in the NYC
Irish community, and his mother is from Kiltamagh County Mayo, Ireland.

Frank received the Irish American Business Chambers 2015 Taoiseach Award
from Anne Andersen, Ireland Ambassador to the USA, for his leadership in
the Irish Business community. In 2014, Frank received a life-time
achievement award from the American Spinal Injury Association for his
invention of the NeuroScaffold, the first treatment to restore function
in humans after traumatic spinal cord injury. In 2010, Ireland President
Mary McAleese awarded Frank the 2010 Irish Life Science 50 Award. Since
2005, he’s won a variety of Irish Entrepreneurship Awards. In addition,
Frank won trophies and medals for Irish step dancing as a child and
performed at Irish shows at Carnegie Hall in the 1970s.

Irish culture, organizations and activities have been major impact on
Frank’s success. “After being paralyzed in 1992 and emerging from bed in
1999, I reconnected to the real world through Irish business networks
and activities,” said Frank Reynolds, “the Irish helped re-launch my
life. I developed a treatment for paralysis with the help of Irish
minds, and as I say every day, “Irish scientists rule!”

The NeuroRelease^TM Platform: Non-Addictive
and Non-opiate Treatment of Pain
NeuroRelease^TM is a
morphine replacement, and non-addictive pain platform for the
surgical/hospital setting, or for acute and chronic pain. First product
FDA approval for the platform will be for a 14-day post-surgical pain
treatment and it is expected in late 2018.

Major Benefits of NeuroRelease^TM

• Effects only sensory signals
• No effect on locomotion nerve fibers, so patients can enter physical
  therapy quickly
• Maintains two-point discriminate touch so patients can function
• No effect on proprioception so no effect on a person feeling of
  well-being

Therefore, patients will maintain two-point discriminate touch, control
of their locomotion nerve fibers so they control voluntary movement to
enter rehabilitation quickly with a non-addictive morphine replacement.
PixarBio’s NeuroRelease^TM pain platform also includes 4-8
hour, 3-day, 7-day, 14-day and 90-Day pain treatments all have expected
FDA approvals in 2020. NeuroRelease^TM is biodegradable, and
it’s non-toxic so NeuroRelease^TM can be re-injected to extend
treatment timelines.

PixarBio Corporation is in the process of preparing to trade publicly in
mid- October and our stock symbol will be PXRB. PixarBio Corporation was
awarded the Boston Business Journal’s « 2016 Best Places to Work ». The
award recognizes PixarBio as one of the region’s best firms, offering
the greatest professional opportunities and work environments to
innovate.

About PixarBio Corporation
PixarBio is a specialty
pharmaceutical/biotechnology company focused on 505(b)2; pre-clinical
and commercial development of novel neurological drug delivery systems
for post-operative pain. PixarBio researches and develops
targeted delivery systems for drugs, cells, or biologics to treat pain,
epilepsy, Parkinson’s disease, and spinal cord injury. Our lead product
platform, NeuroRelease™, has achieved sustained therapeutic release of
non-opiate drugs for post-operative, acute and chronic pain in
pre-clinical models. For more information, visit www.pixarbio.com.

Safe Harbor Statement
This announcement includes
“forward-looking statements” within the meaning of the safe harbor
provisions of the United States Private Securities Litigation Reform Act
of 1995. These statements are based upon the current beliefs and
expectations of PixarBio’s management and are subject to significant
risks and uncertainties. If underlying assumptions prove inaccurate or
risks or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of Biotech and
medical device industry regulation and health care legislation in the
United States and internationally; global trends on cost containment;
technological advances, new products and patents attained by
competitors; challenges inherent in new product development, including
obtaining regulatory approval; PixarBio’s ability to accurately predict
future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign risk;
dependence on the effectiveness of PixarBio’s patents and other
protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.

PixarBio Corp undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be obtained through PixarBio’s Corp HQ at 200 Boston Ave,
Suite 1875 in Medford, MA 02155. PixarBio Corp is a private corporation.

PixarBio Corporation – 200 Boston Avenue, Suite 1875 – Medford, MA 02155
617-401-0050
– investorrelations@pixarbio.com
– www.pixarbio.com

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161004005443/en/